Chronic myelocytic leukemia is a clonal proliferation of hematopoietic stem cells caused by myeloproliferative disorders.
慢性粒细胞白血病是一种造血干细胞克隆性增殖所致的骨髓增殖性疾病。
Conditions included myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia, and bronchial carcinoma.
疾病可引发脊髓发育不良、脊髓增殖失调，急性髓性白血病和支气管瘤。
There is high frequency of JAK2 V617F mutation in myeloproliferative disorders and it could be used as the diagnostic marker for myeloproliferative disorders.
JAK2基因V617F突变在骨髓增殖性疾病中有较高的检出率，可作为骨髓增殖性疾病特异性诊断指标。
So SHP-2 could be the key element of the high value-added signal-regulated in myeloid cells and a important regulatory in the pathogenesis of myeloproliferative disorders.
因此，SHP-2可能是髓系细胞高增殖性信号调控的关键分子，及髓系增殖性疾病的发病机制中重要的调控分子之一。
It has been reported in association with acute myeloid leukemia, myeloproliferative disorders, and myelodysplasia in blast transformation, as well as in patients with no known hematological disorders.
它曾被报告与淋巴母细胞转变相关的急性骨髓性白血病、骨髓增生性疾病、脊髓发育不全症等等，甚至于那些不具已知的血液学异常相关的病人们身上。
It has been reported in association with acute myeloid leukemia, myeloproliferative disorders, and myelodysplasia in blast transformation, as well as in patients with no known hematological disorders.
它曾被报告与淋巴母细胞转变相关的急性骨髓性白血病、骨髓增生性疾病、脊髓发育不全症等等，甚至于那些不具已知的血液学异常相关的病人们身上。
应用推荐